Navigation Links
Atherothrombosis Patients at High Risk for CV Events

A large, international study finds that patients with arterial disease have relatively high risk of experiencing a cardiovascular// event (such as heart attack, stroke or cardiovascular death) within one year. This study is published in the March 21 issue of JAMA.

Atherothrombosis (arterial disease, such as coronary artery disease [CAD], cerebrovascular disease [CVD], and peripheral arterial disease [PAD]; narrowing of the arteries that supply the legs and feet]) is associated with the main causes of death on a worldwide scale, according to background information in the article.

"Recent U.S. data have confirmed that, despite a decrease in age-standardized national death rates, the absolute number of deaths from these conditions continues to increase, and prevalence is sharply increasing in other parts of the world. Thus, atherothrombotic diseases are, and are projected still to be, the leading cause of death worldwide by 2020." Few studies have documented the current cardiovascular (CV) event rates in outpatients with atherothrombosis.

Ph. Gabriel Steg, M.D., of the H?pital Bichat-Claude Bernard, Paris, and colleagues examined the characteristics and CV event rates of patients for whom 1-year follow-up data were available from the Reduction of Atherothrombosis for Continued Health (REACH) Registry, an international group of 68,236 patients with either established atherosclerotic arterial disease (such as CAD, PAD, CVD; n = 55,814) or at least three risk factors for atherothrombosis (n = 12,422). The participants were enrolled from 5,587 physician practices in 44 countries in 2003-2004.

As of July 2006, 1-year outcomes were available for 95 percent (n = 64,977) of participants. The researchers found that in the overall stable population with established arterial disease, approximately 1 in 7 patients had a cardiovascular event (CV death, heart attack, and stroke) or was hospitalized for a CV event or revascularization procedure within a year of enrollment. Patients with established arterial disease experienced 2 to 3 times higher event rates than patients with multiple risk factors only.

The overall combined CV death, heart attack, or stroke rate at 1 year was 4.24 percent, ranging from 2.15 percent of patients with multiple risk factors only to 6.47 percent of patients enrolled with CVD and 4.69 percent for those with established atherosclerotic arterial disease.

Among patients with established disease, CV death, heart attack, or stroke rates were 4.52 percent for patients with CAD and 5.35 percent for patients with PAD. The incidences of CV death, heart attack, or stroke or of hospitalization for atherothrombotic event(s) were 15.20 percent for CAD, 14.53 percent for CVD, and 21.14 percent for PAD patients with established disease. These event rates increased directly with the number of symptomatic arterial disease locations, from 5.31 percent for patients with risk factors only, to 12.58 percent for patients with one, 21.14 percent for patients with two and 26.27 percent for patients with three symptomatic arterial disease locations.

"The high event rates observed in this large, stable, contemporary outpatient cohort of patients with established atherosclerotic arterial disease or with multiple atherothrombotic risk factors indicate that continued efforts are needed to improve secondary prevention and clinical outcomes. Initiatives to improve adherence to evidence-based guidelines and care are an important tool in this respect. In addition, the strong association of asymptomatic and symptomatic multiple locations of atherothrombosis with event rates suggests that atherothrombosis should be addressed as a global arterial disease in patients," the authors conclude.

Source-Eurekalert
PRI
'"/>




Related medicine news :

1. Atherothrombosis Associated With High Rates of Cardiovascular Events
2. One in Three Heart Attack Patients Have No Chest Pains
3. Amphetamines Help Recovery of Stroke Patients
4. Painkillers Do Not Shorten Dying Patients Lives
5. Patients With Filariasis More Prone To HIV Infection
6. Glivec - New Hope For CMC Patients
7. Patients often assume wrongly that they are allergic to penicillin
8. New FDA Approved Drug NATRECOR For Heart Failure Patients
9. Hemochromatosis Patients Blood is Safe
10. Patients Pressure Would Result In Overprescription
11. Risk Of Decongestants In Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... NY (PRWEB) , ... October 13, 2017 , ... Ellevate ... people in business to advocate for action towards gender equality at their inaugural Summit ... from around the globe, and reached a social audience of over 3 million. To ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... 2017 , ... The American College of Medical Informatics (ACMI) will present the ... Opening Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium ... a pioneer in the field of medical informatics, this prestigious award is presented to ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform for ... the first annual edition of its Global CSR Risk and Performance Index. ... by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points ... ... ...
Breaking Medicine Technology: